p53 mutations do not predict response to paclitaxel/ radiation for nonsmall cell lung carcinoma

Cancer

Volumn 78, Issue 6, 1996, Pages 1203-1210

  Safran, Howard ^a,d   King, Thomas ^a   Choy, Hak ^b   Gollerkeri, Ashwin ^a,c   Kwakwa, Helena ^a   Lopez, Frances ^a   Cole, Bernard ^a   Myers, James ^a   Tarpey, Joseph ^a   Rosmarin, Alan ^a  

^a BROWN UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c YALE CANCER CENTER   (United States)

^d MIRIAM HOSPITAL   (United States)

Author keywords

combined modality therapy; lung neoplasms; p53; paclitaxel; radiotherapy

Indexed keywords

CARBOPLATIN; PACLITAXEL; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CELL DEATH; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; COMBINED MODALITY THERAPY; EXONS; FEMALE; FORECASTING; GENES, P53; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PACLITAXEL; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RADIATION-SENSITIZING AGENTS; REMISSION INDUCTION; SEQUENCE ANALYSIS, DNA;

EID: 9544220646     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960915)78:6<1203::AID-CNCR6>3.0.CO;2-A     Document Type: Article

References (53)

1. Schaake-Koning C, Bogaert WVD, Dalesio O, Festen J, Hoogenhout J, Houtte PV, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992;326:524-30.
2. Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 1995;13:452-8.
3. Hazuka MB, Crowley JJ, Bunn PA, O'Rourke M, Braun TJ, Livingston RB. Daily low dose cisplatin plus concurrent high dose thoracic irradiation in locally advanced unresectable non-small cell lung cancer: results of a phase II Southwest Oncology Group Study. J Clin Oncol 1994;12:1814-20.
4. Trovo MG, Minatel E, Franchin G, Gobitti C. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24:11-5.
5. Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W, et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995;13:1425-9.
6. Legha SS, Tenny DM, Krakoff IR. Phase I study of Taxol using a five-day, intermittent schedule. J Clin Oncol 1986;4:762-6.
7. Forastiere AA, Urba SG. Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol 1995;22(Suppl 6):24-7.
8. Donehower R, Rowinsky EK, Grochow L, Longnecker SM, Ettinger DS. Phase I trial of Taxol in patients with advanced cancer. Cancer Treat Rep 1987;71:1171-7.
9. Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo D, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992;10:1165-70.
10. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;84:1797-1805.
11. Chang A, Kim K, Glick J, Anderson T, Karp D. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer. J Natl Cancer Inst 1993;85:388-93.
12. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993;85:384-7.
13. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
14. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91:479-87.
15. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD. Investigation of Taxol as a potential radiation sensitizer. Cancer 1993;71:3774-8.
16. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol 1994;12:2682-6.
17. Choy H, Browne MJ. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol 1995;22(Suppl 6):70-5.
18. Choy H, Safran H. Preliminary analysis of a phase I/II study of weekly paclitaxel (Taxol) and concurrent radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol 1995;27:55-8.
19. Geard CR, Jones JM, Schiff PB. Taxol and radiation. J Natl Cancer Inst 1993;15:89-94.
20. Tishler R, Schiff P, Geard C, Hall E. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992;22:613-7.
21. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441-6.
22. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
23. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ cdk-4. Nature 1993;386:704-7.
24. Kinzler KW, Vogelstein B. Clinical implications of basic research, cancer therapy meets p53. Science 1994;331:49-50.
25. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
26. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
27. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
28. Lowe SW, Ruley HE, Jacks T. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-67.
29. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
30. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
31. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY. Loss of heterozygosity of chromosome 3p markers in small cell lung cancer. Nature 1987;329:451-3.
32. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-21.
33. Kawasaki M, Nakanisi Y, Kuwano K, Takayama K, Yatsunami J, Hara N. The utility of p53 immunostaining for the transbronchial biopsy specimens of lung cancer: p53 overexpression may predict poor prognosis and chemoresistance in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1996;15:94.
34. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-57.
35. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-9.
36. Lenz HJ, Danenberg KD, Leichman L, Leichman C, Hayashi K, Metzger D, et al. p53 status and thymidylate synthase levels are predictors of chemotherapy efficacy in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1996;15:216.
37. Imamura I, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood 1994;84:2412-21.
38. Fung CT, Fisher D. p53: from molecular mechanism to prognosis in cancer. J Clin Oncol 1995;13:808-11.
39. Fisher DE, Bodis S, Lowe S, Takemoto C, Housman D, Jacks T. Restoration of apoptosis in p53 deficient tumor cells. ASH Proc 1994;84:430.
40. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996;2:72-9.
41. Deisseroth AB, De Vita VT. The cell cycle. Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. Can J Sci Am 1995;1:15-21.
42. Preudhomme C, Dervite I, Wattel E, Vanrumbeke M, Flactif M, Lai JL, et al. Clinical significance of p53 mutations in newly diagnosed Burkitts lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol 1995;13:812-20.
43. Lowe S, Schmitt EM, Smith W, Osborne BA, Jacks T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 1993;362:847-50.
44. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362:849-52.
45. WAF1 and p53 requires c-raf-1. Cancer Res 1995;55:4623-6.
46. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a frequent tartet for genetic abnormalities in lung cancer. Science 1989;246:491-6.
47. Richardson GE, Johnson BE. The biology of lung cancer. Semin Oncol 1993;20:105-27.
48. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
49. Mitsudomi T, Steinberg SM, Nau MM. p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992;7:171-80.
50. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 1990;5:1603-10.
51. Marchetti A, Buttitta R, Merlo G, Diella F, Pellegrini S, Pepe S, et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 1993;53:2846-51.
52. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992;52:4828-31.
53. Safran H, King T, Choy H, Sikov W, Hesketh P, Wolfe B, et al. Phase I study of paclitaxel and concurrent radiation for locally advanced gastric and pancreatic cancer. ASCO Proc 1996;15:442.